Long-term follow-up of quality of life in high-risk patients undergoing transcatheter aortic valve implantation for symptomatic aortic valve stenosis by de Ronde-Tillmans, M.J. (Marjo J. A G) et al.
 Journal of Geriatric Cardiology (2018) 15: 261267 
 ©2018 JGC All rights reserved; www.jgc301.com 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology 
Research Article     Open Access  
 
Long-term follow-up of quality of life in high-risk patients undergoing  
transcatheter aortic valve implantation for symptomatic aortic valve stenosis   
 
Marjo JAG De Ronde-Tillmans1, Tom AJ de Jager1, Jeannette A Goudzwaard², Nahid El Faquir1,  
Nicolas M van Mieghem1, Felix Zijlstra1, Elisabeth MWJ. Utens3,4, Francesco US Mattace-Raso2,  
Mattie J Lenzen1, Peter PT de Jaegere1  
1Erasmus Medical Center, Department of Cardiology, Thorax Center, Rotterdam, the Netherlands 
2Erasmus Medical Center, Section of Geriatrics, Department of Internal Medicine, Rotterdam, the Netherlands 
3Erasmus Medical Center, Department of Child and Adolescent Psychiatry/Psychology, Sophia Children’s Hospital, Rotterdam, the Netherlands 
4The Netherlands Research Institute of Child Development and Education, University of Amsterdam, the Netherlands  
 
Abstract 
Background  Transcatheter aortic valve implantation (TAVI) has become the standard treatment for patients with severe symptomatic 
aortic stenosis (AS) considered at very high risk for surgical aortic valve replacement. The purpose of this sub-study was to evaluate 
long-term (> 4 years) health-related quality of life (QoL) in octogenarians who underwent TAVI. Methods  A single center observational 
registry in twenty patients who underwent frame analysis assessment ≥ 4 years after TAVI. Health-related QoL was evaluated, using the 
Short Form-36 (SF-36), the EuroQoL-5D (EQ-5D) and the visual analogue score (EQ-VAS) questionnaires. Results  The mean SF-36 sub-
scale scores at follow-up were physical functioning 40.8 ± 26.3, role physical functioning 67.7 ± 34.9, vitality 54.6 ± 21.6, general health 
52.1 ± 20.4, social functioning 63.8 ± 37.7, role emotional functioning 70.2 ± 36.0, mental health 73.2 ± 23.3 and bodily pain 80.9 ± 22.9. 
The mean EQ-VAS score > 4 years after TAVI was 64.7 ± 15.1. With respect to functional class, 80% of the patients were in NYHA class 
I/II at follow-up compared to 15% prior to TAVI. Conclusions  This sub-study reports a significant improvement in functional class 
(NYHA) in a selected group of very elderly patients > 4 years after TAVI. Furthermore, all patients showed a satisfactory QoL despite their 
age and multiple comorbidities. In addition, our study reveals a lower QoL when compared with the general age matched Dutch population. 
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1  Introduction 
Degenerative aortic valve stenosis is a very common 
valvular heart disorder in adults aged > 65 years in indus-
trialized countries, with a prevalence rate of 3%–9%.[1,2] 
Surgical aortic valve replacement (SAVR) has been the 
standard of care for these patients. However, at least one 
third of the patients are considered too high at risk or in-
operable for SAVR due to multiple comorbidities. In the 
last decade, transcatheter aortic valve implantation (TAVI) 
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has emerged as a less-invasive treatment for these patients  
with > 300,000 procedures performed to date. Importantly, 
its use is still growing,[3–6] as the field of TAVI is rapidly 
evolving due to improvements in catheter and valve tech-
nology, procedural techniques and refined patient selection. 
Consequently, knowledge of long-term structural device 
integrity and patient-reported outcomes are important to 
guide this development.[7,8] 
Most patients undergoing TAVI are octogenarians with 
multiple co-morbidities and reduced health related quality 
of life (QoL).[9] In these patients, the importance of QoL 
may be as or even more important than survival.[10,11] 
Moreover, meaningful long-term benefit of QoL post- 
TAVI is of importance to guide patient-centered deci-
sion-making as well as identifying predictors for improve-
ment of QoL post-TAVI. Yet, information on true long- 
term results is lacking.  
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Accordingly, we initiated study on the long-term integ-
rity of the self-expanding Medtronic CoreValve System 
(Medtronic Inc. Minneapolis MN) to analyse QoL and func-
tional health status at a minimum of 4 years after TAVI.[12] 
The main objective of this sub-study is to investigate 
long-term health related quality of life and functional health 
status. A sub-analysis was performed to compare QoL of 
participants with the general age matched Dutch population. 
2  Methods 
Between November 2005 and March 2012, a total of 259 
patients with severe symptomatic aortic valve stenosis re-
ceived a TAVI in the Erasmus Medical Centre, Rotterdam. 
After checking survival status in January 2016 at the Mu-
nicipal Civil Registry, survivors were evaluated for assess-
ment of long-term valve function (transthoracic echocardi-
ography) and frame integrity of the self-expanding 
CoreValve (Multi Slice Computed Tomography―TACT 
study).[12]  
Only patients who underwent TAVI > 4 years earlier 
were eligible. Given the nature of the study that included 
MSCT, patients with renal failure, known hypersensitivity 
or contraindication to intravenous contrast in addition to 
patients with previous stroke, a language barrier and treat-
ment with a valve other than the self-expanding CoreValve 
were not included in the present study. Patients who ful-
filled these study-criteria were contacted for both long-term 
valve & frame analysis and health-related status. The Medi-
cal Ethics Committee approved the study (MEC-2013-331) 
and all participants signed the informed consent. After writ-
ten informed consent, patients were scheduled for a one-day 
out-patient visit during which data on valve function, health 
status and QoL were collected. A sub-analysis was per-
formed to compare the measured health related QoL at fol-
low-up in TACT patients with the general Dutch population 
as stratified by age > 70 years. No data on baseline QoL was 
available. 
2.1  Baseline characteristics 
Socio-demographic characteristics included gender and 
age. Cardiovascular risk factors included: diabetes mellitus, 
hypertension, pulmonary vascular disease, previous stroke, 
atrial fibrillation, previous pacemaker, chronic obstructive 
pulmonary disease, pulmonary hypertension and chronic 
kidney disease. Clinical characteristics included: history of 
coronary artery disease, peak aortic valve velocity, left ven-
tricular ejection fraction, NYHA classification and Log Eu-
roSCORE (European System for Cardiac Operative Risk 
Evaluation). All data on baseline and the medical history of 
patients were collected from the medical records.  
2.2  Health status 
Health-related QoL was measured with the generic Short 
Form 36 Health Survey (SF-36) and the EuroQoL-5-di-
mensions-5 levels (EQ-5D-5L) questionnaires. The SF-36 
questionnaire is a validated and widely accepted instrument 
to measure overall physical and mental health status. It con-
sists of 36 items, which measures eight health-related di-
mensions covering physical functioning, role physical, bod-
ily pain, general health, role emotional, social functioning, 
vitality and mental health. Each item is scored in a 0–100 
range, with higher scores reflecting a better QoL.[13]  
The EQ-5D-5L is a generic health utility QoL instrument 
and is qualified for measuring health status within an elderly 
population (EuroQoL Group, Rotterdam, The Netherlands).[14] 
This descriptive system consists of five domains (i.e., mo-
bility, self-care, usual activities, pain/discomfort, and anxi-
ety/depression) each of which is divided in five levels of 
functioning [i.e., no problems (level 1), some or moderate 
problems (level 2 and 3), and severe or extreme problems 
(level 4 and 5)]. Theoretically, 3125 different health status 
can be generated by this classification, which can be con-
verted to a utility score, ranging from 0.446 to 1 (a value 
of 1 indicating full health, while a value lower than 0 repre-
sents a status considered to be worse than death). The sec-
ond part of the EQ-5D includes a visual analog scale 
(EQ-VAS), ranging from 0 (“Worst imaginable health state”) 
to 100 (“Best imaginable health state”).[15] Both SF-36 and 
EQ-5D, questionnaires were administered and collected 
during in-person visits > 4 years after TAVI.  
2.3  Statistical analysis 
Continuous variables are expressed as mean ± SD. Di-
chotomous variables are presented as numbers and per-
centages. To evaluate differences between TACT partici-
pants and surviving non-participants chi-square tests, stu-
dents t-test or Mann-Whitney tests were applied as appro-
priate. P < 0.05 was considered statistically significant. All 
analyses were performed using SPSS version 21 for Win-
dows (SPSS Inc, Chicago, IL). 
3  Results 
3.1  Patient characteristics 
Of the 259 patients who underwent TAVI between 
2005 and 2012, 158 (61%) patients died before the time of 
inclusion (January 2016) with a mean survival time for the 
total cohort of 4.7 years (95% CI: 4.16–5.14). Out of the  
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Figure 1.  Study flowchart of number of total TAVI patients 
between 2005 and 2012, non-responders (n = 81) and the final 
study population with more than 4 years follow-up data post- 
TAVI (n = 20). TAVI: transcatheter aortic valve implantation. 
101 remaining patients, 81 patients did not participate in 
the TACT study due to exclusion criteria or non-response. 
Other reasons were the lack of social support or due to 
physical or mental disabilities. The remaining 20 patients 
with a mean follow-up period of 5.5 years (range 4–10 
years) provided written informed consent and were in-
cluded in the current analysis (Figure 1).  
Baseline data of all 101 patients are shown in Table 1, 
including a comparison between participants (n = 20) in 
the TACT sub-study and surviving non-participants (n = 
81). Most patients suffered from multiple comorbidities 
and high surgical risk (mean logistic EuroSCORE 15.4% 
± 9.8%). The mean age at the time of TAVI was 80 ± 8.0 
years, and almost half were men. The majority of partici-
pants (77%) had a poor functional status (NYHA III/IV) 
before TAVI. Overall, there were no significant differ-
ences on baseline characteristics between participants and 
surviving non-participants, except for left ventricular ejec-
tion fraction (LVEF).  
3.2  (Post-) Procedural outcomes 
On post-procedural outcomes no differences between 
participants and non-participants were found. As shown in 
Table 2, all participants underwent successful TAVI with 
femoral access, general anesthesia as standard of care at  
Table 1.  Baseline patient characteristics. 
 Total population (n = 101) Non-participants (n = 81) Participants (n = 20) P-value
Mean age, yrs 79.7 ± 8.0 80.2 ± 8.0 77.9 ± 7.7 0.26 
Male sex 49 (49%) 38 (47%) 11 (55%) 0.52 
Body mass index, kg/m2 26.8 ± 3.9 26.5 ± 3.4 27.9 ± 5.3 0.16 
Cardiovascular risk factors     
Diabetes mellitus 21 (21%) 18 (22%) 3 (15%) 0.48 
Hypertension 60 (59%) 47 (58%) 13 (65%) 0.57 
PVD 8 (8%) 7 (9%) 1 (5%) 0.59 
Previous stroke 20 (20%) 15 (19%) 5 (25%) 0.52 
Atrial fibrillation 22 (22%) 17 (21%) 5 (25%) 0.70 
Previous pacemaker 12 (12%) 9 (11%) 3 (15%) 0.63 
COPD 21 (21%) 15 (19%) 6 (30%) 0.26 
PHT 7 (7%) 5 (6%) 2 (10%) 0.55 
Chronic kidney disease 16 (16%) 12 (15%) 4 (20%) 0.57 
History of CAD 50 (50%) 38 (47%) 12 (60%) 0.30 
Peak AoV, m/s 4.3 ± 0.8 4.3 ± 0.8 4.3 ± 0.9 0.75 
LVEF 51.7% ± 14.1% 53.7% ± 12.7% 44.4% ± 17.0% 0.01 
NYHA classification    0.30 
I / II 23 (23%) 20 (25%) 3 (15%)  
III / IV 78 (77%) 61 (75%) 17 (85%)  
Logistic EuroSCORE 15.4% ± 9.8% 14.5% ± 9.5% 18.9% ± 10.8% 0.07 
Data are presented as mean ± SD or n (%) unless other indicated. AoV: Aortic valve velocity; CAD: coronary artery disease; COPD: chronic obstructive pul-
monary disease; EuroSCORE: European System for Cardiac Operative Risk Evaluation; LVEF: left ventricular ejection fraction; NYHA: New York Heart 
Association; PHT: pulmonary hypertension; PVD: pulmonary vascular disease. 
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Table 2.  Procedural and post-procedural outcomes. 
 Total population (n = 101) Non-participants (n = 81) TACT-participants (n = 20) P-value 
Procedural outcomes     
Access trans femoral 100 (99%) 80 (99%) 20 (100%) 0.62 
Pre-dilatation 97 (98%) 78 (98%) 19 (95%) 0.49 
MCV 97 (96%) 77 (95%) 20 (100%) 0.31 
Device success 98 (97%) 78 (98%) 20 (100%) 0.38 
Post-dilatation 14 (14%) 9 (11%) 5 (25%) 0.11 
Total contrast, cc 135 ± 68.5 132.9 ± 69.1 146.3 ± 66.7 0.47 
Procedure time 193 ± 65.0 190.9 ± 65.3 203.4 ± 64.7 0.47 
Post-procedural outcomes     
Aortic valve regurgitation    0.58 
Mild 27 (27%) 22 (28%) 5 (25%)  
Moderate/severe 6 (6%) 4 (5%) 2 (10%)  
Permanent pacemaker 15 (15%) 11 (14%) 4 (20%) 0.47 
Bleeding more than 1 day    0.85 
Minor 9 (9%) 7 (9%) 2 (10%)  
Major 11 (11%) 9 (11%) 2 (10%)  
Life threatening 6 (6%) 4 (5%) 2 (10%)  
Major vascular complication 6 (6%) 5 (6%) 1 (5%) 0.58 
Place of discharge    0.61 
Home 91 (90%) 71 (88%) 20 (100%)  
Other location 10 (10%) 10 (12%) 0 (0%)  
Length of stay, days 9.2 ± 5.1 9.0 ± 4.3 10.4 ± 7.6 0.28 
Data are presented as mean ± SD or n (%) unless other indicated. MCV: Medtronic CoreValve. 
 
that time, a mean procedure time of 203 ± 64.7 min and a 
mean hospitalization time of 10.4 ± 7.6 days. Post-pro-
cedural complications included one participant with a 
major vascular complication and four participants who 
required a permanent pacemaker. Major bleeding after 
more than one day occurred in six participants of which 
two were life threatening. 
3.3  Health status 
The SF-36, EQ-5D-5L and EQ-VAS scores are shown in 
Table 3. The mean SF-36 subscale scores at follow-up were 
physical functioning 40.8 ± 26.3, role physical functioning 
67.7 ± 34.9, vitality 54.6 ± 21.6, general health 52.1 ± 20.4, 
social functioning 63.8 ± 37.7, role emotional functioning 
70.2 ± 36.0, mental health 73.2 ± 23.3 and bodily pain 80.9 
± 22.9. With attention to EQ-5D, mobility was found to be 
the most frequent reported limitation (75%) while self-care 
was the least frequent reported limitation (35%). The major-
ity of the participants had moderate limitations in all sub- 
domains. The mean utility index and EQ-VAS score were 
0.69 ± 0.29 and 64.7 ± 15.1. Table 3 also shows a comparison 
of the QoL in TACT participants with the mean QoL values 
of the age adjusted Dutch population. With respect to func-
tional class expressed by NYHA, 80% had mild symptoms 
(class I or II) at follow-up versus 15% before TAVI, indi-
cating a significant functional improvement (Table 1 and 3). 
4  Discussion  
The main findings of the present study in a selected 
group of octogenarians who underwent TAVI > 4 years ago 
because of severe AS are a significant improvement in 
functional class (NYHA) and a satisfactory QoL.  
Although we recognize that the herein included patients 
represent a selected group of TAVI patients, this study con-
firms the improvements reported in other studies but over a 
longer period of time.[16–18] Indeed, previous studies mainly 
focus on the first post-procedural period (up to one year) 
while in this study the mean follow-up time was 5.5 years. 
The improvement in functional class and the findings in 
health related outcome is noteworthy given the age and co-
morbid conditions in these patients. In line with others, sus-
tainable improvement of NYHA class has been observed in 
long-term survivors, as NYHA class I/II has been observed 
in most patients, who were in NYHA III/IV prior to 
TAVI.[19,20] This indicates that these patients, despite multi-
ple comorbid conditions and advanced age, clearly benefit 
from this invasive procedure. 
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Table 3.  Quality of Life Scores at follow-up (6 years) in 
TACT-participants. 
 
TACT-subgroup 
(n = 20) 
Dutch population*
SF-36 
Physical functioning 40.8 ± 26.3 58.9 ± 30.8 
Role physical functioning 67.7 ± 34.9 56.9 ± 44.0 
Vitality 54.6 ± 21.6 61.8 ± 23.6 
General health 52.1 ± 20.4 58.9 ± 21.1 
Social functioning 63.8 ± 37.7 75.6 ± 27.0 
Role emotional functioning 70.2 ± 36.0 74.5 ± 38.2 
Mental health 73.2 ± 23.3 73.0 ± 19.9 
Bodily pain 80.9 ± 22.9 68.1 ± 27.4 
EQ-5D (% of patients indicating a problem) 
Mobility 75.0% 36.5% 
Self-care 35.0% 11.7% 
Usual activities 65.0% 26.0% 
Pain/discomfort 60.0% 48.5% 
Anxiety/depression 40.0% 3.6% 
Utility score 0.69 ± 0.29 0.85 ± 0.15 
VAS 64.7 ± 15.1 72.9 ± 24.3 
NYHA classification   
I/II 16 (80%)  
III/IV 4 (20%)  
Data are presented as mean ± SD or n (%) unless other indicated. *Dutch 
population norms for the SF-36 are stratified by age > 70 years;[29] Dutch 
population norms for the EQ-5D are stratified by age > 75 years.[15] EQ-5D: 
EuroQoL 5 Dimensions; SF-36: Short Form (36) Health Survey; VAS: 
Visual Analogue Score.  
 
With respect to health-related QoL, the majority of the 
participants showed satisfactory QoL scores > 4 years 
after TAVI. In addition, our study reveals a lower QoL 
when compared with the general age adjusted Dutch popu-
lation.[15] Ware, et al.[21] described that a 5-point difference 
between groups or a 5-point change over time is consid-
ered clinically and socially relevant. Our participants 
scored lower on most SF-36 subscales and all EQ-5D 
subdomains when compared to the Dutch population as 
stratified by age > 70 years.[15,22] The differences in health 
scores on the physical scales of the SF-36 are more than five 
points and therefore should be considered clinically and 
socially relevant. With attention to bodily pain, the partici-
pants scored higher on the SF-36 subscale. A possible ex-
planation is that patients are getting used to their physical 
limitations and multiple comorbidities,[23,24] which could 
result in a lower sensitivity for pain. These findings indicate 
that within elderly people, large QoL differences exist and 
may under scribe the need for more long-term follow-up 
research, with standardized QoL instruments specific de-
veloped for patients with AS. 
In comparison, the Partner study was the first to show a 
substantial improvement of QoL at 1-year follow-up after 
either TAVI or SAVR in high-risk elderly patients.[25] Base-
line EQ-5D utility score increased by 14% to 0.66 at 1-year 
post-TAVI. Fairbairn, et al.[18] had shown that QoL, as 
measured with the EQ-5D and EQ-VAS, improved early 
after TAVI and was maintained at 1-year post-TAVI. The 
German TAVI registry revealed that patients with a low 
baseline EQ-5D had a significantly better improvement in 
QoL one year after TAVI.[17]  
Other studies also showed a significant improvement at 
one-year follow-up in all SF-36 domains with higher sum-
mary scale scores than the general population-norms.[26,27] 
Unfortunately, we could not perform an age- and co-mor-
bidity matched comparison precluding firm conclusions or 
interpretation. Of note, the mean age of the reference data 
in the general Dutch population is standardized to 70+ 
whereas the mean age in our population was 79.7 years. It 
is important to note that an increase in age is associated 
with a decrease in QoL, indicating a decline in the slope 
of people’s self-rated health over the decades of their 
life.[15] Mangen, et al.[28] reported that impairment increases 
rapidly with age, but health status is also associated with 
socio-demographic variables and comorbidities. These 
findings are consistent with our findings that increasing 
age and multiple co-morbidities can be associated with 
lower QoL.  
4.1  Limitations  
Our study is a single-center study and based on a small 
group of selected patients (20 participants of long-term sur-
vivors) most likely representing a group of most vital pa-
tients who agreed to participate in a clinical research project. 
Therefore selection bias may have occurred. Second, our 
analyses are based on a population including the first TAVI 
patients in the Netherlands. All procedures were performed 
under general anesthesia in patients with an extremely 
high-risk status and therefore might not represent a con-
temporary TAVI population. 
4.2  Conclusions 
This sub-study in a selected group of very elderly pa-
tients who underwent frame analysis assessment ≥ 4 years 
after TAVI reports significant improvement in functional 
class (NYHA). Furthermore, all patients showed a satisfac-
tory quality of life despite their age and multiple comorbid-
ities. In addition, our study reveals a lower QoL when com-
pared with the general age matched Dutch population. The 
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observed improvement in functional status reflects a posi-
tive long-term outcome of TAVI in this selected group of 
octogenarians. These benefits should be taken into account 
when discussing the indication for elderly patients undergo-
ing TAVI. Further research is warranted on long-term 
health-related QoL in a high-risk population with aortic 
stenosis.  
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